Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries

This article was originally published in PharmAsia News

Executive Summary

Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries

You may also be interested in...

Serum Institute Of India Chairman Cyrus Poonawalla On How To Succeed In The Vaccines Business: An Interview With PharmAsia News

In a rare interview, Serum Institute of India Chairman Cyrus Poonawalla discusses his determination to keep vaccine prices low for India’s masses and his ongoing battles with multinational pharma companies.

GAVI Alliance Builds On Matching Fund On Heels Of Pfizer And GSK Vaccine Deal For Developing Countries

GAVI brings on new funding partners for immunization, supplementing expanded pneumococcal vaccine supply agreements with Pfizer and GSK.

As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot

Bharat Biotech's rotavirus development is a public-private initiative with partners including the Indian government, CDC and NIH.

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts